VTGN News and Press, VistaGen Therapeutics Inc. From 05/24/23

Mental Health America’s prestigious national certification complements Vistagen’s ongoing efforts to improve mental health care across the U.S. Timely recognition comes during Mental Health Awareness Month and MHA’s nationwide efforts to fight stigma and provide suppo...

Results from new study further support that fasedienol acts locally in the nasal passages and does not require systemic uptake or direct activity on neurons in the brain to achieve fast-acting anti-anxiety effects Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical comp...

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that the European Patent Office (&#...

Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) has granted the Company a p...

VistaGen Therapeutics (NASDAQ: VTGN ), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting positive feedback from the U.S. Food an...

Vistagen plans to use the LSAS as the primary efficacy endpoint for a Phase 3 clinical study designed to evaluate fasedienol as a treatment for the overall control of symptoms of social anxiety disorder (SAD) FDA provides helpful guidance on key aspects of potential NDA-enabling devel...

2023-03-23 06:00:00 ET 3 Things to Look For When Buying Penny Stocks in 2023 Penny stocks have always been a tantalizing prospect for investors, offering the potential for significant returns on small investments. In 2023, the market landscape continues to evolve, making it all the more...

2023-03-22 11:13:40 ET VistaGen Therapeutics ( NASDAQ: VTGN ) jumped ~17% on Wednesday morning after announcing data from a Phase 3 trial for its experimental nasal spray for social anxiety disorder (SAD), fasedienol (PH94B), in adults. As for its primary endpoint, the t...

Long-term intranasal administration of fasedienol, used as-needed up to four times a day in daily life, was safe and well-tolerated in nearly 500 patients with social anxiety disorder (SAD) Patients self-administered over 30,000 doses of fasedienol in real-world settings , with a mean...

VistaGen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced key updates regarding its phase 1 clin...